No. of cases	
92	
8	
47.2(16.0-73.0)	
99	
1	
79	
0	
54	
46	
47	
53	
86	
14	
	8 47.2(16.0-73.0) 99 1 79 0 54 46 46 47 53

Supplementary Table 1. Clinical and Pathological Features of the 100 HCC Cases

Gene	Name	Sense	Antisense
GAPDH	Glyceraldehyde	acccactcctccacctttga	tccaccaccctgttgctgta
	3-phosphatase		
	dehydrogenase		
IGF1R	Insulin like growth factor 1	agactgaacctctgttgccag	tggggtcagggagaaatcct
	receptor		
DROSHA	Drosha ribonuclease III	gaccaagtattcagcaagcgg	agtctagggtcacaatctggg
XPO5	Exportin 5	gcattgctgggtgcagattc	ggctccccaagtcatctgag
DICER	Dicer	tcgagcacatgagaccaacc	atggtcatccagttcgccaat
pri-miR-378	Primer-microRNA-378	ggtggtgccgcaagagaatc	tgcaggaacaaccagaacat
			ct
U6	U6 small nuclear RNA	ctcgcttcggcagcaca	aacgcttcacgaatttgcgt

Supplementary Table 2. List of the Primers Used for Real-time Quantitative PCR

The primers were designed using Primer3 v.0.4.0 (http://bioinfo.ut.ee/primer3-0.4.0/primer3) and purchased from Tsingke.

Supplementary Table 3. List of the Primers Used for microRNA Real-time Quantitative PCR

Gene	Sense
nicroRNA-378a-3p	actggacttggagtcagaaggc
microRNA-342-3p	tctcacacagaaatcgcaccc
microRNA-23b-5p	tgggttcctggcatgctgat
microRNA-7977	ttcccagccaacgcacca
microRNA-708-3p	gggcccaactagactgtgagc
Precusor-microRNA-378a-3p	tgagggctcctgactccagg
ōs	gggaataccgggtgctgtaggct

The primers were designed designed on the basis of a study by Shi and collaborators

(Shi et al., 2011) and purchased from Tsingke.

Supplementary	Table 4 Antibodies	used in the paper
---------------	---------------------------	-------------------

Antibody	Catalogue number	Company
IGF1R	#9750	CST
Cleaved PARP (Asp214)	#5625	CST
ERK1/2	#4695	CST
pERK1/2(pT202/pY204)	#4370T	CST
Akt (pan)	#4691	CST
Phospho-Akt (Ser473)	# 4060	CST
Exportin-5	ab129006	Abcam
β-Tubulin	AT809	Beyotime

Supplemental Figure and Figure Legends




Figure S1. (A) Fluorescence microscopy image post-miR-378a-3p transfection and incubation with sorafenib for 48 h; (B) IGF1R inhibitor (NVP-ASW742) significantly blocked the miR-378a-3p inhibitor-mediated sorafenib resistance of HCC cells; (C) si-XPO5 did knockdown the XPO5. (D) The expression of XPO5 under transfected different concentration of siRNA; (E) The viability of Huh7-SR cells under transfected different concentration of siRNA.




Figure S2. (A) the ALT level of four groups; the weight of four groups; (B) Schematic representation of the PDX model timeline; (C) gross view of tumors from two groups; Liver view of tumors from two groups; (D) Immunohistochemistry showed combination therapy could suppress HCC metastasis, proliferation, IGF1R level and TUNEL assay in PDX model.




Figure S3. We used IHC experiment to measure the expression level of IGF1R in the 100 tumoral samples. The expression level was rated as 0 for negative, 1 for mild positive, 2 for positive, 3 for severe positive. Score 0 and 1 were considered as low expression, while score 2 and 3 were included in high expression.